Patients who agree to participate will be scheduled for a procedure called an endoscopic ultrasound (EUS). The EUS is performed in the Gastroenterology Endoscopy Unit. The EUS screening is not standard of care. While the EUS screening is experimental in this study, EUS is approved for screening for other indications. Participants will be given anesthesia, and once sedated, an ultrasound scope will be passed through the participant’s mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. At the same time patients sign the consent to be in the research study, they will be given a procedural consent to sign so that a biopsy may be performed to obtain a diagnosis in the event the EUS shows an abnormality. It is standard of care to biopsy the abnormal growth. To prepare for the EUS, participants need to stop eating and drinking at midnight the night before the procedure. Participants will need to be off certain medications, such as Coumadin, Plavix, aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) at least 5 days before the procedure is scheduled. If the initial EUS is normal, participants will have a repeat EUS on a yearly basis unless the results become abnormal. If the results become abnormal, participants will be treated according to standard medical therapy.